VYGR vs. ITOS, REPL, JSPR, CCCC, OCGN, SLDB, TSHA, ADPT, VALN, and EDIT
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include iTeos Therapeutics (ITOS), Replimune Group (REPL), Jasper Therapeutics (JSPR), C4 Therapeutics (CCCC), Ocugen (OCGN), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), Valneva (VALN), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
iTeos Therapeutics (NASDAQ:ITOS) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.
iTeos Therapeutics presently has a consensus target price of $30.33, indicating a potential upside of 191.67%. Voyager Therapeutics has a consensus target price of $19.33, indicating a potential upside of 150.11%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe iTeos Therapeutics is more favorable than Voyager Therapeutics.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 10.2% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Voyager Therapeutics has a net margin of 52.93% compared to Voyager Therapeutics' net margin of 0.00%. iTeos Therapeutics' return on equity of 63.89% beat Voyager Therapeutics' return on equity.
Voyager Therapeutics received 348 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 72.50% of users gave iTeos Therapeutics an outperform vote while only 67.44% of users gave Voyager Therapeutics an outperform vote.
iTeos Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
In the previous week, Voyager Therapeutics had 9 more articles in the media than iTeos Therapeutics. MarketBeat recorded 10 mentions for Voyager Therapeutics and 1 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.30 beat Voyager Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.
Voyager Therapeutics has higher revenue and earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Voyager Therapeutics beats iTeos Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
